Overview

Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)

Status:
Unknown status

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

Patients being hospitalized for acute heart failure and already receiving standard therapy will be randomized to receive either tolvaptan or placebo, based on the level of copeptin measured in their bloodstream. Patients with high copeptin levels will be able to participate in the trial, patients with low levels will be excluded. Patients being admitted to the observation unit for acute heart failure and already receiving standard therapy will be randomized to receive either tolvaptan or placebo without consideration of the copeptin level. The hypothesis is that patients receiving tolvaptan will have better improvement of shortness of breath than those receiving placebo, within 9 hours of drug administration.

Phase:

Phase 3

Details

Lead Sponsor:

Maisel, Alan, M.D.

Collaborators:

Otsuka Pharmaceutical Development & Commercialization, Inc.
Thermo Fisher Scientific

Treatments:

Tolvaptan